Good decisions require good information
Find hidden gems and smart strategies from top experts when you join Seeking Alpha.
LEGN Legend Biotech CorporationStock Price & Overview
$56.61
LEGN Stock Price
Quant Ranking
LEGN Analysis
LEGN News
Latest Headlines
![Stephen Ayers profile picture](https://static1.seekingalpha.com/images/users_profile/048/050/289/big_pic.png?io=w36)
Ratings Summary
People Also Follow
Similar to LEGN
ETFs Holding LEGN
LEGN Company Profile
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.
LEGN Revenue
LEGN Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Growth
Profitability
Momentum
Capital Structure
Dividends
LEGN Ownership
LEGN Peers
Risk
Technicals
LEGN Transcripts
Investor Presentations
LEGN SEC Filings
Press Releases
LEGN Income Statement
LEGN Balance Sheet
LEGN Cash Flow Statement
LEGN Long Term Solvency
Discover More
You may be interested in: